Palvella CSO to Present at FDA Workshop on Drug Repurposing
Event summary
- Palvella Therapeutics' CSO Jeff Martini, Ph.D., selected to present at FDA public workshop on drug repurposing on August 5, 2026.
- Workshop focuses on selecting and prioritizing promising FDA-approved drugs for repurposing in rare diseases.
- Dr. Martini will discuss evidence frameworks and regulatory approaches for advancing repurposed therapies.
- Meeting builds on FDA’s May 2026 drug repurposing initiative aimed at accelerating patient access to effective therapies.
The big picture
Palvella’s participation in the FDA workshop underscores the growing emphasis on drug repurposing as a strategy to accelerate therapeutic development for rare diseases. The initiative aligns with broader industry trends toward leveraging existing molecules for new indications, particularly where significant unmet medical needs exist. Palvella’s focus on novel formulations of well-characterized drugs positions it at the forefront of this regulatory and scientific shift.
What we're watching
- Regulatory Strategy
- How FDA’s evolving framework for drug repurposing will impact development timelines and approval pathways.
- Execution Risk
- Whether Palvella can leverage its expertise in rare diseases to advance its pipeline through regulatory hurdles.
- Industry Trends
- The pace at which drug repurposing initiatives gain traction in addressing unmet medical needs in chronic and rare diseases.